CBC Group buys UCB's China mature neurology and allergy arm
The $680m deal includes UCB's brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and its Zhuhai manufacturing site, and was made in partnership with Mubadala Investment Co.
December 03, 2024